Last reviewed · How we verify
HER-096
At a glance
| Generic name | HER-096 |
|---|---|
| Sponsor | Herantis Pharma Plc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease (PHASE1)
- Single Ascending Doses of HER-096 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HER-096 CI brief — competitive landscape report
- HER-096 updates RSS · CI watch RSS
- Herantis Pharma Plc. portfolio CI